DYNE THERAPEUTICS INC

DYNNASDAQ

🏆 #1199 by market capEarnings Nov 4US Equity

$26.94▲ $0.23 (+0.86%)

Live

1h▼ 0.4%

24h▲ 0.9%

7d▲ 3.1%

14d▲ 7.3%

30d▲ 13.9%

1y▲ 131.7%

🏦Market Cap

$5.03B

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Weak

Trading Snapshot

Day Range: $26.81 – $27.27
52-Week Range: $10.78 – $27.09
Volume: $3.61B
Avg Volume: $2.89B
Shares Outstanding: 186.8M
Next Earnings: Aug 31, 2026

Fundamentals Snapshot

Annual Revenue: $399M
Last Q Revenue: $111M
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-3.33
Dividend Yield: —

Why Investors Own DYN

✓High-growth profile — revenue up +50.6% YoY with expanding US Equity exposure.
✓Healthy economics — 48% gross margin and 8% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$399M▲ +44.0% YoY

Gross Margin (TTM)

48.1%▲ +4.3% YoY

Operating Income (TTM)

$56M▲ +44.0% YoY

Free Cash Flow (TTM)

$34M▲ +44.0% YoY

About DYNE THERAPEUTICS INC

Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases. The company was founded in 2017 and maintains its corporate headquarters in Waltham, Massachusetts.

🦦